| Title | Genetic polymorphism and lung cancer risk: assessment of the enzymes’ NAT2 and CYP2A6 metabolizing activity in a case-control phenotyping study in a Greek population | |
| Authors | E. Malliara¹, K. Balaskonis¹, E. Haliassos¹, S. Bauer², C. Skarleas³, K. Kyprianou³ and N. Drakoulis¹
1. University of Athens, School of Pharmacy, Greece 2. Charite University Medicine Berlin, Germany 3. Euromedica Hospital, Athens, Greece |
|
| Citation | Malliara, E., Balaskonis, K., Haliassos, E., Bauer, S., Skarleas, C. et al: Genetic polymorphism and lung cancer risk: assessment of the enzymes’ NAT2 and CYP2A6 metabolizing activity in a case-control phenotyping study in a Greek population, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 244-245 (2006) | |
| Publication Date | Accepted for publication: 19-20 May 2006 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | NAT2, CYP2A6, polymorphism, lung cancer, chemical carcinogenesis. | |
| Other Terms | review article | |
| Summary | Most people are constantly exposed to chemical carcinogens in their everyday lives, but only a small proportion of them finally develop cancer. Interindividual differences in the pre-carcinogens’ biotransformation might modify the susceptibility to lung cancer of individuals exposed to such substances. These activation and detoxification reactions are mostly catalyzed by polymorphic phase I and phase II enzymes. This study aimed at exploring the association between the activity of NAT2 and CYP2A6 metabolizing enzymes and lung cancer risk in the Greek population. 99 histologically verified lung cancer patients (17 females and 82 males, aged 45-85y, median age 65y) of Greek origin and 390 Greek Caucasians (219 females and 171 males, aged 19-83y, median age 50y), free of malignancy were phenotyped using the non-invasive in vivo caffeine test. The NAT2 phenotyping revealed a clear bimodal distribution with a significantly lower frequency of slow acetylators among Greek lung cancer patients (26%) compared to control subjects (47%). This observation (OR=0.41 p<0.001) indicated a positive impact of high NAT2 activity on lung cancer susceptibility. Only 4.87% of the control group exhibited low activity of the CYP2A6 enzyme. The frequency of PMs among lung cancer patients was 4.04% indicating a not significant association (OR=0.84 p=0.85) between CYP2A6 activity and lung cancer risk. | |
| References | 1. International Agency for Research on Cancer, World Health Organization. Chemicals and industrial processes associated with cancer in humans. IARC Monographs vol. 1-20. Report of an ad hoc working group. Lyon, International Agency for Research on Cancer, 1979
2. Roots I., Drakoulis N., Brockmoller J.: Pharmacogenetics of drug metabolism. Chapter 33: polymorphic enzymes and cancer risk: concepts, methodology and data review. In: International Encyclopedia of Pharmacology and Therapeutics. P. 815, 1992 3. Turesky R.J.: The role of genetic polymorphisms in metabolism of carcinogenic heterocyclic aromatic amines. Curr. Drug Metabol. 5: 169-180 (2004) 4. Grant D.M., Tang B.K., Kalow W.: (1984) A simple test for acetylator phenotype using caffeine. Br. J. Clin. Pharmacol. 17: 459-464 (1984) 5. Drakoulis N., Malliara E., Balaskonis K., Haliassos E., Bauer S., Skarleas C., Kyprianou K.: Genetic polymorphism and chemical carcinogenesis: assessment of the enzymes’ NAT2, CYP2A6 and CYP1A2 Metabolizing Activity among Greek Lung Cancer patients and controls. Basic Clin. Pharm. Taxical. 97: 115 (2005) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|